Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus.
Reactivation of hepatitis B viral infection (HBVr) is a known risk in cancer patients with a history of chronic hepatitis B infection receiving cytotoxic or immunosuppressive therapies. Patients with hematologic malignancies or those who have received stem cell transplantation seem to be most at risk but reactivation has been reported with various malignancies. Reactivation can present as asymptomatic liver function test abnormalities (LFTs), with symptoms of abdominal pain, encephalopathy, or as fulminant hepatitis and liver failure. Here we report the first case of a patient with islet cell tumor on octreotide and sirolimus who developed hepatitis B reactivation with fulminant liver failure and death.
Department of Medicine, Memorial Sloan Kettering Cancer Center, Gastroenterology and Nutrition Service, New York, NY 10065, USA.
Ersilia M
EM
DeFilippis
Department of Medicine, Memorial Sloan Kettering Cancer Center, Gastroenterology and Nutrition Service, New York, NY 10065, USA.
Emmy
E
Ludwig
Hepatitis B; antiviral agents; islet cell; octreotide; sirolimus